Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Penfluridol→

Penfluridol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
26864-56-2
Molecular formula
C28H27ClF5NO
Molecular weight
523.97 g/mol
Drug class
Long-acting diphenylbutylpiperidine antipsychoticdopamine D2 receptor antagonist
Mechanism of action
Blocks central dopamine D2 receptors, reducing dopaminergic neurotransmission in pathways associated with psychotic symptoms. Its long duration of action supports intermittent oral dosing.
Indications / reported uses
  • Maintenance or long-term treatment of schizophrenia and other psychotic disorders where penfluridol remains authorised.

Sources: https://meshb.nlm.nih.gov/record/ui?ui=D010395 · https://www.ncbi.nlm.nih.gov/mesh/68010395

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Penfluridol Environmental Risk Assessment (ERA) (the Penfluridol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.